Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Cervical cancer prevention should focus on vaccinating adolescent girls

Cervical cancer prevention should focus on vaccinating adolescent girls

August 21, 2008

Screening policies also need revision

Boston, MA -- The cost-effectiveness of vaccination in the United States against human papillomavirus (HPV), a sexually-transmitted virus that causes cervical cancer, will be optimized by achieving universal vaccine coverage in young adolescent girls, by targeting initial "catch-up" efforts to vaccinate women younger than 21 years of age, and by revising current screening policies, according to an analysis by Harvard School of Public Health (HSPH) researchers in the August 21, 2008 issue of The New England Journal of Medicine.




In the U.S. in 2007, cervical cancer developed in more than 11,000 women and killed 3,600 women. Cervical cancer is caused by infection with high-risk "oncogenic" types of HPV, also associated with other cancers. Worldwide, HPV types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancer cases. Vaccines against HPV-16 and HPV-18 appear to be highly efficacious in preventing HPV-16 and HPV-18 infections and cervical disease in females who have not previously been infected with these types. The quadrivalent vaccine currently licensed in the U.S. also prevents low-risk HPV types 6 and 11 (HPV-6 and HPV-11) infections, which are responsible for most genital warts and juvenile-onset recurrent respiratory papillomatosis (JORRP), a rare but severe respiratory condition usually diagnosed in infancy that may be related to a mother's infection with genital warts.

Cervical cancer prevention in the U.S. has traditionally relied on a screening program involving frequent cytology (Pap smear) and/or HPV DNA testing, recommended annually or biennially for sexually-active women. HPV vaccination raises questions regarding the age at which to vaccinate females, target groups for temporary catch-up programs, and appropriate changes to screening practices.

Jane Kim, assistant professor of health decision science in the Department of Health Policy and Management at HSPH, led the study which involved synthesizing epidemiologic, clinical, and demographic information using sophisticated computer-models that simulate the U.S. population. The models were used to predict the health and economic outcomes of HPV vaccination of preadolescent girls (i.e., 12 years of age) and catch-up vaccination over a 5-year period for girls and women over 12 years of age, in the context of routine cervical cancer screening; strategies differed in the upper age of catch-up programs, to ages 18, 21, or 26 years. While the study focused on the prevention of cervical disease, the investigators also examined the benefits of the quadrivalent vaccine on genital warts and possible benefits of averting other HPV-related cancers and JORRP.

A novel part of this study involved examining how uncertain scenarios might impact the appropriate policies for the U.S., such as the duration of vaccine protection and whether or not a booster dose will be needed, whether or not the vaccine will also prevent infections with other HPV types, and what might occur to rates of cancer if women change their screening practices after being vaccinated.

Kim and co-author Sue Goldie, professor of health decision science at HSPH, found that vaccination against HPV-16 and HPV-18 would lead to lower cervical cancer rates and be economically attractive if high coverage can be achieved in the most important target group of 12-year-old girls, and if vaccine protection against infection lasted for at least 20 years. The study predicted that if most 12-year-old girls were vaccinated, their future cervical cancer screening could begin somewhat later than currently recommended and be conducted less frequently (i.e., every 3 to 5 years).

At an additional expense, a catch-up program for girls between 13 and 18 years of age appears to offer benefits and be reasonably cost-effective compared to other vaccine programs in the U.S. The cost-effectiveness of extending the catch-up program to 21 years of age is less certain, and depends on whether the vaccine will eventually be proven to prevent other cancers caused by HPV-16 and -18. Including women to age 26 was consistently not cost-effective because the vaccine is quite expensive, but is less effective in women who are already sexually active. Current CDC recommendations and a recent CDC summary suggest routine vaccination of girls aged 11-12 and catch-up vaccination of girls and women aged 13 to 26.

There is no absolute criterion that dictates whether a vaccine or public health intervention is cost-effective in the U.S.; however, most policy-makers agree that interventions that have a cost-effectiveness ratio less than $50,000 per quality-adjusted life year (QALY) gained, a metric used to describe cost-effectiveness, are very good value for money. While vaccination of 12-year-old girls was less than this threshold, vaccinating girls into their mid- to late-20s as part of a catch-up program was not.

Kim and Goldie caution that these results could change if future information shows that vaccine protection does not last, or if there is an unexpected increase in other cancer-causing HPV types not included in the vaccine.

Kim emphasizes, "Our results are the best prediction we can make with the information available now, but it will be critical to update the analysis as we learn more about the long-term vaccine effects."

An editorial, Human Papillomavirus Vaccination - Reasons for Caution, by Charlotte J. Haug, MD., PhD. Editor in Chief of the Journal of the Norwegian Medical Association, also appears in this issue of NEJM. A long-term followup study of HPV vaccination is underway in Norway.

Kim and Goldie also emphasize that it will be important to achieve high coverage among all 12-year-old girls, and not just a small subset, and to ensure girls are screened for cervical cancer beginning in their early- to mid-20s, since HPV types not included in the vaccine can still cause cancer. From a public health perspective, if women who are at continued risk for HPV infection and cervical cancer are not regularly screened, and if only some adolescents have access to the vaccine, cervical cancer rates in the U.S. may not change. Ensuring U.S. women equal access to both preadolescent vaccination and adult cervical cancer screening, is imperative.

Harvard School of Public Health



Related Cervical Cancer Current Events and Cervical Cancer News Articles Cervical Cancer Current Events and Cervical Cancer News RSS Cervical Cancer Current Events and Cervical Cancer News RSS
UAB Oncologists Report HPV Vaccine Also Protects Females From Post-Surgical Cancer Recurrence
A vaccine designed to prevent cervical cancer also may protect females from post-surgical recurrence of the disease, according to researchers at the University of Alabama at Birmingham (UAB).

News brief: Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low
The overall potential benefits of human papillomavirus (HPV) vaccinations or frequent HPV screenings for women over the age of 41 are low, concludes a new study published online February 15 in the Journal of the National Cancer Institute.

UH Case Medical Center researchers publish promising findings for advanced cervical cancer
Researchers at the Ireland Cancer Center of University Hospitals (UH) Case Medical Center, have published new findings that may lead to a new standard of care for patients with locally advanced cervical cancer.

Curing More Cervical Cancer Cases May be in the Math
Cervical cancer is highly curable when caught early. But in a third of cases, the tumor responds poorly to therapy or recurs later, when cure is much less likely.

Estrogen in the Fight Against Schizophrenia
Many American women are prescribed estrogen to combat the negative effects of menopause, such as bone loss and mood swings. Now, new evidence from a Tel Aviv University study suggests that hormone replacement therapy might also protect them - and younger women - from schizophrenia as well.

Who's afraid of the HPV vaccine?
A new study concludes that people tend to match their risk perceptions about policy issues with their cultural values, which may explain the intense disagreement about proposals to vaccinate elementary-school girls against human-papillomavirus (HPV).

McGill-CHUM study: 56 percent of young adults in a new sexual relationship infected with HPV
A groundbreaking study of couples led by Professor Eduardo Franco, Director of McGill University's Cancer Epidemiology Unit, in collaboration with a team of colleagues from McGill and Université de Montréal/Centre Hospitalier de l'Université de Montréal (CHUM), found more than half (56 per cent) of young adults in a new sexual relationship were infected with human papillomavirus (HPV).

Childhood Vaccine Schedule Updated; UAB Infectious Disease Doctor on Panel
he co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases is a member of the committee that this week issued updated guidelines for childhood and teen immunizations to include formal recommendations that children older than 6 months get the H1N1 influenza vaccine to guard against swine flu, and that combination vaccines are generally preferred over separate injections.

Biodegradable particles can bypass mucus, release drugs over time
Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body's sticky and viscous mucus secretions to deliver a sustained-release medication cargo.

Papillomavirus silences innate immune response
In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to degenerate.
More Cervical Cancer Current Events and Cervical Cancer News Articles
100 Questions & Answers Abourt Cervical Cancer (100 Questions & Answers about . . .)

100 Questions & Answers Abourt Cervical Cancer (100 Questions & Answers about . . .)
by Don S. Dizon (Author)

The only text to provide both the patient and doctor views, 100 Questions & Answers About Cervical Cancer aims to provide a much needed primer for patients and their families and aims to address the questions most relevant to a woman following a diagnosis of pre-invasive changes or invasive cervical cancer. This text gives up-to-date, authoritative, practical answers to your questions about cervical cancer; not only the diagnosis and treatment of the disease, but also female survivorship. This is an invaluable resource for anyone coping with the physical and emotional turmoil of this disease.

What Every Woman Should Know about Cervical Cancer

What Every Woman Should Know about Cervical Cancer
by Nenad Markovic (Author), Olivera Markovic (Author)

Recent introduction of HPV vaccines has raised hopes for immunization against cervical cancer and for the first time in the history of humanity for eradication of one malignant disease. This new “opportunity” has changed many current views on cervical cancer prevention, control diagnosis and treatment. Many canons and guidelines became subject of review and many revisions are coming. This book is intended to summarize most of these events and to present them to all women in a language understandable by the eneral public.

We expect the book will bring all readers the rationale for optimism and will provide guidance as how to gain knowledge and skills for critical thinking and making an educated decision when it will be necessary in their lives.



Crying in the Shower-Cervical Cancer

Crying in the Shower-Cervical Cancer
by Pamela Ayer (Author)

My book contains my personal story from the day of detection of cervical cancer until the day I became a cancer survivor.

Understanding Cervical Cancer Anatomical Chart- Paper unmounted

Understanding Cervical Cancer Anatomical Chart- Paper unmounted
by Anatomical Chart Company



Johns Hopkins Patients' Guide to Cervical Cancer

Johns Hopkins Patients' Guide to Cervical Cancer
by Colleen McCormick (Author), Robert Giuntoli (Author)

Johns Hopkins Patients' Guide to Cervical Cancer is a concise, easy-to-follow how to guide that puts you on a path to wellness by explaining cervical cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.

Damaged Goods?: Women Living With Incurable Sexually Transmitted Diseases

Damaged Goods?: Women Living With Incurable Sexually Transmitted Diseases
by Adina Nack (Author)

How do women living with genital herpes and/or HPV (human papillomavirus) infections see themselves as sexual beings, and what choices do they make about sexual health issues? Adina Nack, a medical sociologist who specializes in sexual health and social psychology, conducted in-depth interviews with 43 women about their identities and sexuality with regard to chronic illness. The result is a fascinating book about an issue that affects millions around the world, but is all too little discussed. "Damaged Goods?" adds to our knowledge of how women are affected by living with chronic STDs and reveals the stages of their sexual self-transformation. From the anxiety of being diagnosed with an STD to issues of blame and shame, Nack - herself diagnosed with a cervical HPV infection - shows why...

12 Ribbon Cancer Awareness Charm Chamrs Findings Jewelry Making Bracelets Fundraising (Teal)

12 Ribbon Cancer Awareness Charm Chamrs Findings Jewelry Making Bracelets Fundraising (Teal)
by Knextion

12 piece pack charms. Great for jewelry making, fundraising projects or gift favors!

Cervical Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science)

Cervical Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science)
by Heather Hasan (Author)



Chart -Understanding Cervical Cancer Anatomical Chart- Plastic Laminated

Chart -Understanding Cervical Cancer Anatomical Chart- Plastic Laminated
by Anatomical Chart Company

LFA #96547 Chart - Understanding Cervical Cancer All LFA Charts and Posters are designed to a) Provide just the right level of detail, b) At-a-glance format, c) Striking colorful images, d) Enlarged view of key organs or structures, e) Comprehensive and anatomically/medically accurate. Plastic laminate, 20" x 26" offers flexibility, durability and attractive appearance for medical professionals, patients, students and other specialists. Complete with metal eyelets at top corners for hanging or portable stand display. "Write-on, wipe-off" surface is perfect for classrooms and professional offices. Note: This is a durable plastic laminated wallchart- not simply paper as with other sellers. Washable. Designed to last for many years of use. Shipped in mailing tube. Note: Many charts and...

Cervical Cancer (Deadly Diseases and Epidemics)

Cervical Cancer (Deadly Diseases and Epidemics)
by Juliet Spencer (Author)



© 2010 BrightSurf.com